{"id":"met-glibenclamide-group","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Hypoglycemia"},{"rate":"10-30","effect":"Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)"},{"rate":"<1","effect":"Lactic acidosis"},{"rate":"2-5","effect":"Weight gain"},{"rate":"5-10","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL472","moleculeType":"Small molecule","molecularWeight":"494.01"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metformin decreases hepatic glucose production and improves peripheral insulin sensitivity through AMPK activation and mitochondrial effects. Glibenclamide is a sulfonylurea that stimulates insulin secretion by closing ATP-sensitive potassium channels in pancreatic beta cells. Together, they provide complementary glucose-lowering effects through different mechanisms.","oneSentence":"This combination of metformin and glibenclamide reduces blood glucose by improving insulin sensitivity and stimulating pancreatic insulin secretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:27.432Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT01867502","phase":"PHASE4","title":"Effects of Vildagliptin Versus Glibenclamide on Glycemia After Exercise in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2014-04","conditions":"Diabetes Mellitus, Type 2, Hypoglycemic Agents, Diabetic Blood Glucose Monitoring","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Daonil®","Glucophage"],"phase":"marketed","status":"active","brandName":"MET + Glibenclamide Group","genericName":"MET + Glibenclamide Group","companyName":"Hospital de Clinicas de Porto Alegre","companyId":"hospital-de-clinicas-de-porto-alegre","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination of metformin and glibenclamide reduces blood glucose by improving insulin sensitivity and stimulating pancreatic insulin secretion. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}